Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks Real-World results of prostate cancer combo therapy

NCT ID NCT06380738

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 03, 2026 · Updated 30 times

Summary

This study observes 250 men with metastatic castration-resistant prostate cancer (mCRPC) who are taking the drugs olaparib and abiraterone together as part of their routine care. Researchers will track how long patients stay on this treatment and what therapies they use next. The goal is to understand real-world effectiveness beyond clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Aschaffenburg, Germany

  • Research Site

    RECRUITING

    Augsburg, Germany

  • Research Site

    RECRUITING

    Bergisch Gladbach, Germany

  • Research Site

    RECRUITING

    Berlin, Germany

  • Research Site

    RECRUITING

    Bonn, Germany

  • Research Site

    RECRUITING

    Cologne, Germany

  • Research Site

    RECRUITING

    Dresden, Germany

  • Research Site

    RECRUITING

    Duisburg, Germany

  • Research Site

    RECRUITING

    Eisenach, Germany

  • Research Site

    RECRUITING

    Eisleben Lutherstadt, Germany

  • Research Site

    RECRUITING

    Frankfurt, Germany

  • Research Site

    RECRUITING

    Greifswald, Germany

  • Research Site

    RECRUITING

    Halle, Germany

  • Research Site

    RECRUITING

    Hamburg, Germany

  • Research Site

    RECRUITING

    Hanover, Germany

  • Research Site

    RECRUITING

    Heidelberg, Germany

  • Research Site

    RECRUITING

    Heinsberg, Germany

  • Research Site

    RECRUITING

    Herzogenaurach, Germany

  • Research Site

    RECRUITING

    Leipzig, Germany

  • Research Site

    RECRUITING

    Lübeck, Germany

  • Research Site

    RECRUITING

    Lüneburg, Germany

  • Research Site

    RECRUITING

    Magdeburg, Germany

  • Research Site

    RECRUITING

    Marburg, Germany

  • Research Site

    RECRUITING

    Mülheim, Germany

  • Research Site

    RECRUITING

    Münster, Germany

  • Research Site

    RECRUITING

    Neunkirchen, Germany

  • Research Site

    RECRUITING

    Nuremberg, Germany

  • Research Site

    RECRUITING

    Rüsselsheim am Main, Germany

  • Research Site

    RECRUITING

    Saalfeld, Germany

  • Research Site

    RECRUITING

    Speyer, Germany

  • Research Site

    RECRUITING

    Trier, Germany

  • Research Site

    RECRUITING

    Tübingen, Germany

  • Research Site

    RECRUITING

    Westerstede, Germany

  • Research Site

    RECRUITING

    Wetzlar, Germany

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER